MONTRÉAL, May 27, 2024 /CNW/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce a partnership with Clarius Mobile Health (Clarius) as part of a dedicated effort to aid in early detection of psoriatic arthritis in Canada. By improving access to ultrasound technology, rheumatologists will be able to identify diagnostic markers sooner, and may positively impact the timeline to diagnosis for PsA patients..

MONTRÉAL，2024年5月27日/CNW/-诺华制药加拿大公司很高兴宣布与Clarius Mobile Health（Clarius）建立合作伙伴关系，作为致力于帮助加拿大早期发现银屑病关节炎的一部分。通过改善超声技术的使用，风湿病学家将能够更快地识别诊断标志物，并可能对PsA患者的诊断时间表产生积极影响。。

'At Novartis, we recognize the tremendous potential AI holds for our industry and the healthcare landscape at large,' said Mark Vineis, Country President at Novartis Canada. 'The partnership with Clarius has the potential to transform PsA detection, with the possibility of scaling to other Immunology indications, across specialties and beyond Canada.'.

诺华加拿大公司总裁马克·维尼斯（Mark Vineis）说，在诺华，我们认识到人工智能对我们的行业和整个医疗保健领域的巨大潜力与Clarius的合作关系有可能改变PsA检测，并有可能在加拿大以外的专业范围内扩展到其他免疫学适应症。”。

Novartis and Clarius share a commitment to improving accessibility to medical imaging in Canada. This agreement will facilitate access to handheld ultrasound devices for rheumatologists and deliver a robust training, support and education journey through in-person, virtual and asynchronous events. As a result of the partnership, Novartis will generate evidence to measure and monitor adoption, usage and impact, and determine how usage of ultrasound in routine practice is related to early detection of PsA..

诺华和Clarius共同致力于改善加拿大医学影像的可及性。该协议将有助于风湿病学家使用手持超声设备，并通过面对面、虚拟和异步活动提供强大的培训、支持和教育旅程。作为合作的结果，诺华将提供证据来衡量和监测采用、使用和影响，并确定常规实践中超声波的使用与PsA的早期检测之间的关系。。

'The use of point-of-care ultrasound empowers us as rheumatologists to aid in patient education and adherence, as well as therapeutic confidence, to significantly enhance patient care,' said Dr. Mohammad Bardi, Clinical Instructor at the University of British Columbia and Staff Rheumatologist, Vancouver General Hospital.

不列颠哥伦比亚大学（University of British Columbia）临床讲师、温哥华总医院（Vancouver General Hospital）风湿病学家穆罕默德·巴迪（Mohammad Bardi）博士（Dr.Mohammad Bardi）说，使用即时超声波（point-of-care Ultrasonic）可以使我们作为风湿病学家，帮助患者接受教育和坚持治疗，并增强治疗信心，从而显着提高患者护理水平。

'The Clarius handheld ultrasound enables us to provide the best care possible, especially in settings where access to the sizeable cart-based ultrasound systems is not readily available.'.

“Clarius手持式超声波使我们能够提供尽可能最好的护理，特别是在无法使用大型车载超声波系统的环境中。”。

Clarius is a pioneer in the medical device field, miniaturizing ultrasound technology to improve medical imaging accessibility. Approved by Health Canada in 2022, the third generation Clarius HD3 boasts a product line of high-performance handheld ultrasound scanners that wirelessly connect to clinician Apple and Android smart devices with an AI-powered application.

Clarius是医疗器械领域的先驱，将超声技术小型化，以提高医疗成像的可及性。第三代Clarius HD3于2022年获得加拿大卫生部的批准，拥有高性能手持式超声波扫描仪的产品线，可通过人工智能应用程序无线连接到临床医生的苹果和安卓智能设备。

The Clarius app uses advanced artificial intelligence technology to automatically display an optimized image in real-time, enabling clinicians to make informed decisions at the point of care rather than referring patients to an imaging centre..

Clarius应用程序使用先进的人工智能技术实时自动显示优化的图像，使临床医生能够在护理点做出明智的决定，而不是将患者转介到成像中心。。

'We are inspired by Novartis' mission to improve care for PsA patients and their novel approach to help accelerate diagnosis with real-time ultrasound imaging,' said Ohad Arazi, President and CEO at Clarius. 'We believe that this type of partnership between a pharmaceutical and a medical technology company can play a tremendous role in improving patient outcomes and reducing the burden on our healthcare system..

Clarius总裁兼首席执行官奥哈德·阿拉齐（OhadArazi）说，我们受到诺华改进PsA患者护理的使命以及他们通过实时超声成像帮助加速诊断的新方法的启发我们相信，制药公司和医疗技术公司之间的这种合作关系可以在改善患者预后和减轻医疗保健系统负担方面发挥巨大作用。。

About Novartis

关于诺华

Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram..

诺华是一家专注于创新药物的公司。每天，我们都在努力重新设计医学，以改善和延长人们的生活，从而使患者、医疗保健专业人员和社会在面对严重疾病时获得权力。我们的药物惠及全球2.5亿多人。与我们一起重新想象医学：访问我们https://www.novartis.com并通过LinkedIn、Facebook、X/Twitter和Instagram与我们联系。。

In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit www.novartis.ca.

在加拿大，诺华制药加拿大公司雇用了大约600名员工，以满足患者和医疗保健系统不断变化的需求，每年在该国的研发投资超过3000万美元。有关更多信息，请访问www.novartis.ca。

About Clarius Mobile Health

关于Clarius Mobile Health

Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty. With decades of experience in medical imaging, the team knows that great ultrasound imaging improves confidence and patient care. Today, AI-powered Clarius handheld wireless ultrasound scanners connect to iOS and Android devices, delivering high-resolution ultrasound images traditionally only available with bulkier, high-end systems at a fraction of the cost.

Clarius的使命是为每个专业的所有医疗专业人员提供准确，易于使用且价格合理的超声波工具。凭借数十年的医学成像经验，该团队知道出色的超声成像可以提高信心和患者护理。如今，由人工智能驱动的Clarius手持式无线超声扫描仪连接到iOS和Android设备上，提供高分辨率的超声图像，传统上只能在体积较大的高端系统上获得，成本很低。

Almost 4 million high-definition scans have been performed using Clarius wireless handheld scanners. Clarius scanners are available in over 90 countries worldwide. Learn more at www.clarius.com..

使用Clarius无线手持扫描仪进行了近400万次高清扫描。Clarius扫描仪可在全球90多个国家/地区使用。更多信息，请访问www.clarius.com。。